# EDGAR Filing Document

**Accession Number:** 0001795091
**File Stem:** 0001213900-23-004177
**Filing Date:** 2023-1
**Character Count:** 3293
**Document Hash:** 64dcfbaa4ac27517803942e5b537aa9e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-004177.hdr.sgml**: 20240314

**ACCESSION NUMBER**: 0001213900-23-004177

**CONFORMED SUBMISSION TYPE**: DRSLTR

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OS Therapies Inc
- **CENTRAL INDEX KEY:** 0001795091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **IRS NUMBER:** 825118368
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DRSLTR

**BUSINESS ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 410-297-7793

**MAIL ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OS THERAPIES Inc
- **DATE OF NAME CHANGE:** 20191125

![](image_001.jpg)

EMAIL: SFeldman@olshanlaw.com

DIRECT DIAL: 212.451.2234

January 20, 2023

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: OS Therapies Incorporated<br> <u>Draft Registration Statement on Form S-1</u>

Ladies and Gentlemen:

On behalf of OS Therapies Incorporated, a Delaware corporation (the "Company"), we hereby submit through EDGAR for confidential non-public review under Section 6(e) of the Securities Act of 1933, one complete copy of Confidential Draft Submission No. 2 of the Company's Registration Statement on Form S-1 (the "Registration Statement"), for the registration of shares of the Company's common stock, including one complete copy of the exhibits listed in the Registration Statement as filed therewith.

The Company wishes to bring to the Securities and Exchange Commission's attention that the Registration Statement, as submitted, omits financial information relating to the year ended December 31, 2022, in reliance on Section 71003 of the FAST Act (General Instruction II.C. to Form S-1). The Company has informed us that this information will be filed with the Commission by an amendment to the Registration Statement as soon as the information becomes available for inclusion in the Registration Statement. The Company has asked that we note the reason it is filing the Registration Statement with this deficiency is due to its desire to be able to complete the initial public offering during the early part of the second quarter of 2023. In availing itself of this accommodation, the Company undertakes that it will not distribute a preliminary prospectus for the offering until the Registration Statement has been amended to include the omitted financial information.

Should any member of the Commission's staff have any questions concerning the enclosed materials or desire any further information or clarification in respect of the Registration Statement, please do not hesitate to contact me (tel.: (212) 451-2234) or Paul A. Romness, MPH, the Company's President and Chief Executive Officer (tel.: (703) 541-9811).

Very truly yours,<br>/s/ Spencer G. Feldman<br>Spencer G. Feldman<br>

Enclosures

cc: Mr. Paul A. Romness, MPH<br> Mr. Christopher P. Acevedo

![](image_002.jpg)